Skip to main content

Table 4 Secondary outcome variables

From: Efficacy and safety of oral robenacoxib (tablet) for the treatment of pain associated with soft tissue surgery in client-owned dogs

Variable Time Point (Day: Time) Robenacoxib LSMean Placebo LSMean LSMean Difference P value (RMANCOVA) P value (Wilcoxon Rank Sum)
Total Pain Score 0: 1.5 h 3.89 4.53 −0.648 0.27 0.558
0: 3 h 3.44 4.95 −1.51 0.011* 0.003**
0: 5 h 3.32 4.76 −1.44 0.015* 0.008**
0: 8 h 3.12 4.69 −1.56 0.008** 0.014*
Vocalization Overalla 0.252 0.309 −0.057 0.55 0.482
Attention to Wound/Surgical Site Overalla 0.166 0.208 −0.042 0.47 0.435
Mobility 0: 1.5 h 0.960 0.867 0.093 0.57 0.276
0: 3 h 0.745 0.945 −0.200 0.18 0.392
0: 5 h 0.668 0.936 −0.268 0.072 0.170
0: 8 h 0.607 0.884 −0.276 0.058 0.132
Response to Touch 0: 1.5 h 0.878 1.22 −0.342 0.098 0.128
0: 3 h 0.846 1.46 −0.612 0.003** 0.001**
0: 5 h 0.843 1.45 −0.612 0.003** 0.002**
0: 8 h 0.796 1.48 −0.682 0.001** 0.001**
Demeanor Overalla 0.995 1.13 −0.138 0.17 0.251
Posture/Activity Overallb 0.463 0.816 −0.353 0.006** 0.028*
  1. The Last Observation Carried Forward (LOCF) method was used (see Methods); h hour, LSMean Least Squares Mean
  2. LSMean difference = LSMean of the robenacoxib group - LSMean of the placebo group, RMANCOVA Repeated Measures Analysis Of Covariance
  3. aTreatment x time interaction was not statistically significant (P > 0.05). Therefore, results for the main effect of treatment are presented. The Wilcoxon rank sum test was performed on the median scores for each component obtained for each dog over the period 1.5 h to 8.0 h post-extubation
  4. bTreatment x time interaction was not statistically significant (P = 0.11). However, a statistically significant overall effect of treatment was observed (P = 0.006 via RMANCOVA; P = 0.028 via the Wilcoxon rank sum test)
  5. *Statistically significant at P < 0.05
  6. **Statistically significant at P < 0.01